Tagged with China

Global A new book by two pharma industry experts offers the first truly global perspective on the complexities of market access.   Even the most innovative drug is useless if patients cannot afford or access it. As pharmaceutical innovation advances, market access strategies – determining who gets a drug, at what…

China China’s position as one of the leading global sources and recipients of biopharmaceutical innovation is inarguable. However, in the new Year of the Snake, geopolitical and economic uncertainties are swirling, calling some to question the role that the country can continue to play in global health. Despite these challenging times,…

Japan After 12 years at the helm, Takeda CEO Christophe Weber is stepping down, leaving behind a transformed company. Under his leadership, Japan’s biggest drugmaker expanded globally with the $62 billion acquisition of Shire, made waves with its dengue vaccine QDENGA, navigated the loss of exclusivity on its ADHD blockbuster, and…

Global The 2025 Davos World Economic Forum brought together business leaders from multiple industries to debate the challenges and issues facing the world today. The Pharma CEOs in attendance discussed critical topics such as the impact of climate change on health, AI-driven innovation, and the complexities of global trade tensions, all…

Merck Over the course of its 350-year history, Merck KGaA has expanded from its base in Darmstadt, Germany to establish a strong presence in various markets across the globe. Last year, PharmaBoardroom spoke with Merck affiliate leaders in multiple geographies, uncovering their concerns and priorities as the firm pushed to recover…

China A summary of some of the latest news from China’s pharma industry, including AbbVie’s blood cancer licensing option with Simcere; Lonza’s China manufacturing expansion; Merck’s obesity deal with Hansoh Pharma; Candid Therapeutics’ T-cell engager agreement with WuXi Biologics, and the DLL3-targeted antibody parternship between Innovent Biologics and Roche. AbbVie secures…

Global Regular contributor Brendan Shaw looks ahead to a potentially turbulent 2025 for the pharmaceutical industry, highlighting five key trends that industry stakeholders must carefully navigate over the coming 12 months.   As pharma companies gear up for another year – a year that marks a quarter of the way through…

China Since raising USD 289 million in its Spring 2020 Hong Kong IPO, InnoCare Pharma has had a remarkable rise. Led by a team of Big Pharma veterans and now also listed in Shanghai, the firm has secured regulatory approvals for its BTK inhibitor for haematological cancers in mainland China and…

China US-headquartered global genomic sequencing giant Illumina has endured a tough few years. However, now that various legal wrangles over its acquisition of cancer diagnostics developer GRAIL have been largely resolved and with a new global CEO in place, the firm has outlined a new growth strategy and is predicting high…

China Eye health, despite being essential for most of us in our daily lives, receives significantly less research funding than fields like cancer or diabetes. According to IQVIA, global spending on oncology is expected to reach USD 440 billion by 2028, while ophthalmology will see just USD 38 billion. However, conditions…

China Diabetes is a growing health concern in China and – given the country’s population size – a major contributor to global diabetes levels. Indeed, a recent study in The Lancet estimates that China accounts for almost 18 percent (148 million) of the world’s 828 million diabetics, while World Bank data…

China There are over 7,000 different rare diseases globally, many of which affect only a handful of patients. However, given the scale of China’s population, rare diseases in the country take on an increased significance, something that Chinese policymakers have worked to address in recent years.   “China now introduces new…